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Toll-Like Receptor 9-Independent 
Suppression of Skin Inflammation by 
Oligonucleotides
Andor Pivarcsi1
It has been well established that cytidine-phosphate-guanosine (CpG) oligode-
oxynucleotides (ODNs) activate innate and adaptive immune responses in kerati-
nocytes by stimulating Toll-like receptor 9 (TLR9)-dependent signaling pathways. 
However, as Dorn et al. report, keratinocytes possess another, yet uncharacter-
ized, TLR9-independent mechanism for the recognition of ODNs. Surprisingly, 
the activation of the pathway leads to suppressed chemokine production in vitro 
and decreased skin inflammation in vivo.
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In the past decade, a series of compel-
ling studies has demonstrated that bac-
terial DNA containing unmethylated 
cytidine-phosphate-guanosine (CpG) 
motifs have the capacity to activate host 
defense mechanisms leading to innate 
and acquired immune responses. CpG 
motifs are prevalent in bacterial but 
not in vertebrate DNA, where they are 
reduced in frequency and most often are 
methylated. Currently, Toll-like receptor 
9 (TLR9) is the only known receptor to 
detect immunostimulatory DNA such as 
bacterial DNA. The immunomodulatory 
effects of natural bacterial DNA can be 
mimicked by oligodeoxynucleotides 
(ODNs) containing unmethylated deox-
ycytidyl-deoxyguanosine (CpG) motifs 
(CpG ODNs) (Krieg, 2002). Because 
TLR9 is localized in endosomal com-
partments, stimulation of immune cells 
by CpG ODN requires internalization. 
ODN internalization occurs spontane-
ously in cell culture within minutes of 
exposure without the need for uptake 
enhancers or transfection, is tempera-
ture- and energy-dependent, and seems 
to be relatively sequence-independent. 
After uptake, CpG motifs are recognized 
and bound by TLR9, leading to the 
activation of IFN regulatory factor 5 
(IRF5), tumor necrosis factor recep-
tor-associated factor 6 (TRAF6), and 
NF-κB and the rapid production of 
inflam matory cytokines and chemo-
kines including IL-8/CXCL8, tumor 
necrosis factor-α, IL-6, IL-12, and type 
I IFNs (Vollmer, 2006). 
The vast majority of studies on CpG 
ODNs have investigated its effects on 
professional immune cells such as 
B cells and plasmacytoid dendritic cells. 
To date, relatively few studies have 
reported activation of nonimmune cells 
by CpG ODNs. In recent years, kera-
tinocytes emerged as important play-
ers in innate host defense in the skin. 
Keratinocytes express functional TLRs 
and play an important role in initiat-
ing and modulating/fine-tuning innate 
and adaptive immune responses in the 
skin via secretion of cytokines and che-
mokines in addition to killing microbes 
by producing antimicrobial peptides 
(Pivarcsi et al., 2005). In recent years, 
several studies have reported the expres-
sion of TLR9 in keratinocytes, but its 
biological significance and the effect of 
CpG ODNs on this cell type remained 
uncertain (Mempel et al., 2003; Miller et 
al., 2005). Dorn et al. (2007, this issue) 
investigated whether the known stimula-
tory effect of ODNs on immune cells also 
applies to keratinocytes. Surprisingly, 
the authors observed length- and dose-
dependent suppression of IL-8 produc-
tion by ODNs and demonstrated that 
ODNs had a suppressive effect on skin 
inflammation in a mouse model of con-
tact dermatitis. Considering what we 
knew about TLR9 activation and CpG 
ODNs, these results are unexpected 
and very interesting in themselves. The 
suppression of IL-8 production in kera-
tinocytes was not the only unexpected 
result of the study: ODN-mediated sup-
pression of IL-8 in keratinocytes was 
independent of the CpG motifs and of 
the methylation of ODNs, suggesting 
that TLR9, the canonical receptor for 
foreign DNA in the immune system, is 
unlikely to play a significant role in this 
process. Indeed, transfection of HaCaT 
keratinocytes with dominant-negative 
mutant forms of TLR9 or MyD88 did not 
abrogate the IL-8-suppressing effects of 
CpG and non-CpG ODNs. How can we 
interpret these data?
Immunologists agree that the innate 
immune system possesses a TLR9-inde-
pendent, as-yet-undefined intracel-
lular recognition machinery of DNA 
that induces distinct signaling path-
ways. Recent studies performed with 
TLR9-deficient neutrophils by Alvarez 
et al. (2006) demonstrated that bacte-
rial DNA activates neutrophils by a 
CpG- and TLR9-independent path-
way. In accordance with the results of 
Dorn et al. (2007), their results also 
showed that CpG methylation of bac-
terial DNA did not affect its ability to 
trigger immune responses. Experiments 
aiming to identify the hypothetical 
receptor(s) involved in TLR9-indepen-
dent neutrophil activation by bacterial 
DNA are currently on the way, and it 
is tempting to speculate that similar 
receptors are expressed also by kerati-
nocytes. Interestingly, two DNA-bind-
ing proteins were recently identified in 
keratinocytes by Basner-Tschakarjan et 
al. (2004) that seemed to be involved 
in binding and trafficking of internal-
ized DNA. Further studies are needed 
to identify the physiological role of 
DNA binding as well as the intracel-
lular signaling pathways activated by 
these proteins. Whether these novel 
DNA-binding proteins are involved in 
the IL-8-suppressive effects of ODNs 
that are described by Dorn et al. (2007) 
remains to be determined in prospec-
tive functional studies.
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|Suppression of IL-8 production by ODNs had a suppressive effect 
on skin infl ammation.
Interestingly, another group of inves-
tigators recently demonstrated that the 
expression pattern of TLR9 was differ-
ent in normal and psoriatic skin and 
showed that TLR9 expression, virtu-
ally absent in resting keratinocytes, 
was strongly induced in cultured 
keratinocytes by transforming growth 
factor-α, an important growth factor 
involved in wound healing and in the 
hyperproliferative skin disease pso-
riasis (Miller et al., 2005). Whereas 
CpG ODNs had no stimulatory effect 
on chemokine expression in resting 
keratinocytes expressing TLR9 at a 
low basal level, they strongly induced 
IL-8 production in transforming growth 
factor-α-treated cells with high TLR9 
expression. To date, we cannot provide 
a clear explanation for these contrast-
ing findings. However, it is likely that 
both TLR9-dependent and TLR9-inde-
pendent DNA-recognition pathways 
exist in keratinocytes that mediate pro-
inflammatory and anti-inflammatory 
signaling, respectively. For the time 
being, it is difficult to determine what 
could be the physiological function of 
the two parallel pathways sensing for-
eign DNA. While the evolutionarily 
conserved TLR9-dependent pathway 
is responsible for the activation of 
innate and adaptive immune responses 
to pathogens, we can only speculate 
that the function of the CpG-indepen-
dent, TLR9-independent pathway may 
be the limitation of excessive tissue 
inflammation or induction of toler-
ance to commensal microorganisms. 
The relative importance of these path-
ways may differ in various keratinocyte 
subsets depending on the level of TLR9 
expression. Clearly, future experiments 
are required to characterize and under-
stand the function of this novel DNA-
sensing pathway in keratinocytes.
Another striking feature of the study 
by Dorn et al. (2007) is that both CpG 
and non-CpG ODNs markedly inhibit-
ed ear swelling in a mouse allergic con-
tact hypersensitivity model. Although it 
is clear that the authors have succeed-
ed in suppressing skin inflammation in 
a mouse model of contact dermatitis, 
there are still unanswered questions. 
A wide array of cytokines and chemo-
kines are produced in a coordinated 
and sequential manner at the site of 
allergen exposure that play a pivotal 
role in the induction and initiation of 
contact hypersensitivity, among which 
IL-8 (or its murine functional ortho-
logue) is only one factor. Furthermore, 
IL-8 alone does not cause major inflam-
matory reactions when injected into 
human skin. Therefore, it seems unlike-
ly that effects on the murine functional 
orthologue of IL-8 can explain the anti-
inflammatory effects of ODNs. More 
comprehensive profiling approaches 
are needed to understand the effects of 
ODNs on keratinocytes under resting 
and inflammatory conditions. It will be 
particularly interesting to see whether 
IL-8 is the only inflammatory media-
tor suppressed by CpG and non-CpG 
ODNs or is only the tip of the iceberg 
of proinflammatory cytokines and che-
mokines in the skin. Findings of Dorn 
et al. (2007) showing the activation 
of NF-κB transcription factor in kera-
tinocytes after treatment with ODNs 
suggest that the latter case is true. It is 
likely that a whole cocktail of proin-
flammatory cytokines becomes affect-
ed by ODN treatment, leading to the 
observed anti-inflammatory response. 
Clearly, future studies are needed to 
address these questions.
Many questions remain to be 
answered: There is solid evidence that 
ODNs have inflammatory effects on 
TLR9-expressing professional immune 
cells that are present in the skin, such 
as dendritic cells (Jakob et al., 1998). 
How is it possible that CpG ODNs 
applied to the skin in the present study 
did not have an effect on these cells as 
well? Indeed, other groups have shown 
that intradermal injection of CpG 
ODNs induced increased expression 
of proinflammatory cytokines such as 
IL-1, IL-6, IL-12, and tumor necrosis 
factor-α, and subcutaneous injection of 
CpG ODNs enhanced contact hyper-
sensitivity response in mice (Liu et al., 
2003; Akiba et al., 2004; Klimuk et al., 
2004). As TLR9 is not constitutively 
expressed in the skin, the inflamma-
tory effects observed in these studies 
probably were mediated by infiltrating 
leukocytes expressing TLR9, such as 
antigen-presenting cells. Dorn et al. 
(2007) found the majority of fluores-
cently labeled ODNs localized in the 
epidermis after application onto intact 
mouse skin. Therefore, it seems that, 
depending on the route of application 
and consequently the cell types target-
ed, ODNs can both suppress and stim-
ulate immune responses in the skin.
Comparison of different adjuvants 
in mouse models has demonstrated 
TLR9 stimulation by CpG ODNs to be 
unsurpassed at inducing T-helper 1-
like responses (Krieg, 2006). Numerous 
studies have proved the ability of CpG 
ODNs to eradicate tumors, elicit effi-
cient antiviral responses, or prevent 
and reverse allergen-induced changes 
of acute inflammation in animal mod-
els (Vollmer, 2006). Moreover, clinical 
trials have been initiated, and success-
ful phase I and phase II trials indicate 
that ODNs offer substantial clinical 
benefit in the treatment of cancer and 
infectious diseases as well as in the 
suppression of harmful inflammatory 
responses that characterize asthma and 
other allergic diseases (Krieg, 2006). 
Furthermore, the clinical experience 
to date indicates that CpG ODN treat-
ment of healthy individuals or cancer 
patients does not readily induce auto-
immune disease. Although the report 
of Dorn et al. (2007) leaves us with 
many questions, the success of previ-
ous ODN-based approaches and these 
authors’ results suggest that CpG and/
or non-CPG ODN-based drugs have 
the potential to become a novel way of 
modulating skin inflammation.
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Differentiation of Human 
Keratinocytes Requires the Vitamin D 
Receptor and Its Coactivators
Wendy B. Bollag1,2
1,25-Dihydroxyvitamin D3 exerts its effects by binding to the vitamin D receptor 
(VDR), which regulates transcription of target genes by recruiting various coact-
ivators. Bikle and colleagues examined the role of several coactivators in human 
epidermal keratinocytes and found that, although these coactivators differen-
tially associate with the VDR in proliferating versus differentiating keratinocytes, 
each is required for both early and late differentiation.
Journal of Investigative Dermatology (2007) 127, 748–750. doi:10.1038/sj.jid.5700692
Nuclear hormone receptors constitute 
a family of receptors for which binding 
of ligand induces their interaction with 
specific DNA sequences to modify 
transcription of the genes controlled by 
these response elements. Among a total 
of nearly 50 nuclear hormone receptors 
(Lonard and O’Malley, 2006) are those 
for ligands including estradiol, proges-
terone, testosterone, glucocorticoids, 
mineralocorticoids, thyroid hormone, 
retinoids, peroxisome proliferator-
activated receptor agonists, and, key 
to the article by Hawker et al. (2007, 
this issue), 1,25-dihydroxyvitamin D3. 
The diversity of the nuclear hormone 
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receptor family is an important point 
because many nuclear hormones can 
heterodimerize to form active com-
plexes, and several of these receptors 
in addition to the 1,25-dihydroxyvita-
min D3 receptor (VDR) are known to 
play important roles in the epidermis 
(for instance, retinoids (see, for exam-
ple, Saitou et al., 1995) and peroxi-
some proliferator-activated receptor 
agonists (see, for example, Hanley et 
al., 2000)). Indeed, VDR is known to 
heterodimerize with the retinoid X 
receptor to induce many of its tran-
scriptional changes (although expres-
sion of other genes containing DR6, 
rather than DR3, response elements 
appears to be regulated by the retinoic 
acid receptor rather than the retinoid 
X receptor (reviewed by Bikle et al., 
2004)). Presumably, the capacity to 
heterodimerize with multiple partners 
serves in part to allow the fine-tuning 
of the patterns of gene expression in 
response to nuclear hormone receptor 
ligands in various organs and tissues.
Coactivators, which total approxi-
mately 200 (Lonard and O’Malley, 
2006), appear to serve as links between 
liganded nuclear hormone recep-
tors and the transcription machinery 
to allow regulation of gene expres-
sion, although coactivators may play 
additional roles in other facets of gene 
expression (reviewed by Lonard and 
O’Malley, 2006). One group of coacti-
vators (the steroid receptor coactiva-
tors) recruits cofactors with histone 
acetyl transferase activity and thus 
appears to regulate the accessibility of 
gene promoters to the active nuclear 
receptor–coactivator–transcription 
machinery complex; other coactiva-
tors recruit components of the tran-
scription machinery (for instance, RNA 
polymerase II) to the gene promoter 
(reviewed by Eelen et al., 2006).
There are two primary coactiva-
tor complexes that interact with the 
VDR in keratinocytes (although other 
coactivators may also interact with 
VDR (reviewed by Eelen et al., 2006)). 
The first of these is the D receptor-
interacting protein (DRIP) complex, for 
which DRIP205 (D receptor-interact-
ing protein (205 kilodaltons)) serves 
to anchor the complex to the VDR. The 
other is the steroid receptor coactivator 
